Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows
"we do NOT need to dilute our shareholders by 42% (or any amount) in order to become fully registered and uplisted."
DVD & BluRay New Releases Pipeline (12 Titles, $4,000,000+ Gross Shipments).
New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initial theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS"); in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
VODwiz - Online Independent Films Streaming Portal
- a.) Doubled Titles Library (Second only to Amazon at this point).
- b.) Partnered with Amazon the World's Leading Digital Services Operator.
HHSE VODWIZ welcomes Production Master Technician EARL HALE to our Team!
Greetings Hannover House Friends & Followers - Just in time for the Holidays, we are pleased to announce the engagement of EARL HALE as Technical Services Director for VODWIZ and Hannover House. Earl has an impressive resume in video production, mastering and technical services, including multi-year directorships at Walmart TV and the Media Center of the University of Arkansas Global Campus. A formal press release will post in early January, along with VODWIZ supplier and status news.
Watch this blog for an informative overview on Saturday of Hannover House for the past two years, as well as a sneak-peek into major activities for the company in 2018!
http://hannoverhousemovies.blogspot.com/2017/12/hhse-vodwiz-welcomes-production-master.html ;
MORE VODWIZ - there's another MAJOR STUDIO ALERT in the works! Over the past three years of development, two Major Studios (each offering a small "test quantity" of titles for VODWIZ), were secured to support the initial launch of this streaming operation. Now, we are poised for a very major development of a third Major Studio with over 500 high-profile, ready-to-place titles available for the VODWIZ streaming platform. HHSE key managers (Fred Shefte and Eric Parkinson) are meeting at the studio in southern California on Friday to discuss the logistics of this venture, which is already documented through a participation term sheet.
VODWIZ UPDATE - As anticipated, we have closed a major studio venture that will provide tonnage of product to VODWIZ, including a large quantity of recent, theatrical hits. The totality of programming that will be available to consumers through VODWIZ appears to be on track to being second only to Amazon at this point. We see VODWIZ as a major portal for home entertainment digital streaming access, and potentially "the tail that wags the dog" so to speak. Additionally, we are about a week away from the anticipated finalization of a private funding structure to finance the costs associated with building the VODWIZ website (to Amazon Digital infrastructure standards), and all other pre-launch and initial consumer launch costs for this venture.
11/22/17 HHSE IR BLOG: HHSE NEEDS To UPLIST, but No Dilution By Way Of Merger Required:
http://hannoverhousemovies.blogspot.com/2017/11/and-very-happy-thanksgiving-to-all-hhse.html ;
The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
HHSE. Lots of good stuff in the pipeline
What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initial theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS"); in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
http://hannoverhousemovies.blogspot.com/?m=1
DVD & BluRay New Releases Pipeline (12 Titles, $4,000,000+ Gross Shipments).
VODwiz - Online Independent Films Streaming Portal
- a.) Doubled Titles Library (Second only to Amazon at this point).
- b.) Partnered with Amazon the World's Leading Digital Services Operator.
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED
LOTS TO BE UNLEASHED IN COMING FEW WEEKS!!!!!!!!!!!!!!!
"we do NOT need to dilute our shareholders by 42% (or any amount) in order to become fully registered and uplisted."
DAISY WINTERS WILL MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.
BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture. To be released in January...
DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant)
GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm
THE RIOT ACT is based on the true story of romance, murder and revenge that occurred at the Van Buren Opera House in 1903. The film is planned for an APRIL 27, 2018 Theatrical Release through Hannover House, with top USA Ma
First of all, we'd like to point out that Hannover House is unlike most any other "OTC Pinksheet" listed company. We have been operating continuously since 1993 (24-years) and have been reporting to the OTC Markets since Dec. 2009 (8-years). Statistically, most OTC listed equities are flashes-in-the-pan time wise... lots of Stock Hype / I.R. Promotions, insider share dumps, and quick closures. That's definitely not HHSE.
WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.
HHSE has not issued any new shares in 2.5-years.
"why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initial theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS"); in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED. A GREAT BUYING OPPORTUNITY FOR ANYONE NOT ALREADY LOADED WITH SHARES AND READY FOR THE TAKE-OFF.
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
DAISY WINTERS WILL MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.
"we do NOT need to dilute our shareholders by 42% (or any amount) in order to become fully registered and uplisted."
LOTS TO BE UNLEASHED IN COMING FEW WEEKS!!!!!!!!!!!!!!!
DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!